A Phase 1 interventional study of Andecaliximab and Placebo to match Andecaliximab in Ulcerative Colitis, sponsored by Gilead Sciences. Completed at 16 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-02-01.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 615 studies in Colitis, Ulcerative with a site in United States — 116 open to participants now, 167 under way, 34 of them phase 3. Colitis, Ulcerative · United States.
Among the 615 studies in Colitis, Ulcerative with a site in United States, this one is the 253rd largest by enrollment of the 499 interventional ones that give a count, is one of 23 that started in 2013, is one of 76 in phase 1, and was the 168th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →116 of the 615 studies in Colitis, Ulcerative with a site in United States are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States
Ages 16–80
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
University of Minnesota · Sites in United States
Ages 18+
Muhammad N Aslam, MD · Sites in United States
Ages 18–80
Vanda Pharmaceuticals · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
615 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 87 · Phase 2 173 · Phase 3 132 · Phase 4 33
First in 1995; this study’s year is marked. 23 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is close to the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 76 across the 499 interventional studies, 198 across the 113 observational. Of the 407 that completed or were terminated, 192 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
332 of 615 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 7 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
55 of the studies in Colitis, Ulcerative with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
Add all 55 to your calendar (.ics) → With an account.
Among the 615 studies in Colitis, Ulcerative with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are as follows:
The study will test the safety of the drug. Participants will be given different concentrations of the drug in Cohorts, starting from a lower dose to a higher dose.
Single-Dose Treatment:
A thorough assessment of safety and tolerability will be performed before escalating to the next higher dose. For example, the first 2 participants will be dosed in a staggered fashion 24 hours apart. Provided that there are no significant safety signals up to 24 hours post-dose for the first 2 participants, the remaining 4 participants will be dosed. A thorough assessment of safety and tolerability (through Day 14 post-dose) will be performed by the safety review committee before escalating to the next higher dose. Participants enrolled in a SAD cohort will be eligible to participate in a MAD or adaptive MAD cohort if eligibility criteria are met.
Multiple-Dose Treatment:
This design follows the same set-up as the Single-Dose Treatment. Dosing will not commence in the first MAD cohort until safety data from the second dose level SAD cohort has been reviewed through Day 15. Successive MAD cohorts will only be dosed after safety data from the previous, lower dose MAD cohort through Day 43 and the next higher dose SAD cohort through Day 15, have been reviewed by the safety review committee. An additional Adaptive MAD cohort will explore a subcutaneous dosing of andecaliximab 150 mg prefilled syringe once a week for 5 weeks.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive andecaliximab 0.3 milligrams per kilogram (mg/kg) on Day 1.
Drug: Andecaliximab
Participants will receive andecaliximab 1.0 mg/kg on Day 1.
Drug: Andecaliximab
Participants will receive andecaliximab 2.5 mg/kg on Day 1.
Drug: Andecaliximab
Participants will receive andecaliximab 5.0 mg/kg on Day 1.
Drug: Andecaliximab
Participants will receive placebo on Day 1.
Drug: Placebo to match Andecaliximab
Participants will receive andecaliximab 0.3 mg/kg on Days 1, 15, and 29.
Drug: Andecaliximab
Participants will receive andecaliximab 1.0 mg/kg on Days 1, 15, and 29.
Drug: Andecaliximab
Participants will receive andecaliximab 2.5 mg/kg on Days 1, 15, and 29.
Drug: Andecaliximab
Participants will receive andecaliximab 5.0 mg/kg on Days 1, 15, and 29.
Drug: Andecaliximab
Participants will receive andecaliximab 150 mg on Days 1, 8, 15, 22, and 29.
Drug: Andecaliximab
Participants will receive placebo on Days 1, 15, and 29.
Drug: Placebo to match Andecaliximab
Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection
Also known as: GS-5745
Placebo to match andecaliximab administered by IV infusion
Percentage of Participants Who Experienced Any Treatment-Emergent Adverse Events (TEAEs) (SAD/MAD)
TEAEs are any AEs with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.
Time frame: SAD Cohorts: First dose date (Day 1) plus 30 days, MAD/Adaptive MAD Cohort: First dose date up to last dose date (Maximum: Day 29) plus 30 days
Pharmacokinetic (PK) Parameter: Cmax (SAD)
Cmax is defined as the maximum concentration of drug.
Time frame: Predose and 1, 2, and 6 hours postdose on Day 1; Days 2, 3, 8, 15, 29, and 43
PK Parameter: Cmax (MAD)
Cmax is defined as the maximum concentration of drug over the dosing interval. Data for Day 1 was based on the data collected from Day 1 through Day 8. Data for Day 29 was based on the data collected from Day 29 through Day 36.
Time frame: MAD Cohorts: Predose and 1, 2, and 6 hours postdose on Days 1 and 29, Predose on Days 8 and 36; Adaptive MAD Cohort: Predose and 6 hours postdose on Days 1, and 29, Predose on Days 8 and 36
PK Parameter: Ctau (MAD)
Ctau is defined as the observed drug concentration at the end of the dosing interval.
Time frame: MAD Cohorts: Predose and 1, 2, and 6 hours postdose on Day 29; Predose on Day 36; Adaptive MAD Cohort: Predose and 6 hours postdose on Day 29; Predose on Day 36
PK Parameter: AUCinf (SAD)
AUCinf is defined as the area under the plasma concentration versus time curve extrapolated to infinite time.
Time frame: Predose and 1, 2, and 6 hours postdose on Day 1; Days 2, 3, 8, 15, 29, and 43
PK Parameter: AUCtau (MAD)
AUCtau is defined as the area under the plasma concentration versus time curve over the dosing interval. Data for Day 1 was based on the data collected from Day 1 through Day 8. Data for Day 29 was based on the data collected from Day 29 through Day 36.
Time frame: MAD Cohorts: Predose and 1, 2, and 6 hours postdose on Days 1 and 29; Predose on Days 8 and 36; Adaptive MAD Cohort: Predose and 6 hours postdose on Days 1, and 29; Predose on Days 8 and 36
PK Parameter: AUClast (SAD)
AUClast is defined as the area under the plasma concentration versus time curve from time zero to the last observable concentration.
Time frame: Predose and 1, 2, and 6 hours postdose on Day 1; Days 2, 3, 8, 15, 29, and 43
Participants were enrolled at study sites in the United States, and Europe. The first participant was screened on 28 March 2013. The last study visit occurred on 06 February 2015.
| Milestone | Andecaliximab 0.3 mg/kg IV Single Ascending Dose (SAD) | Andecaliximab 1.0 mg/kg IV (SAD) | Andecaliximab 2.5 mg/kg IV (SAD) | Andecaliximab 5.0 mg/kg IV (SAD) | Placebo Pooled (SAD) | Andecaliximab 0.3 mg/kg IV Multiple Ascending Doses (MAD) | Andecaliximab 1.0 mg/kg IV (MAD) | Andecaliximab 2.5 mg/kg IV (MAD) | Andecaliximab 5.0 mg/kg IV (MAD) | Andecaliximab 150 mg SC (Adaptive MAD) | Placebo Pooled (MAD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 4 | 8 | 8 | 8 | 8 | 10 | 8 |
| Completed | 5 | 4 | 5 | 4 | 4 | 7 | 6 | 7 | 8 | 9 | 5 |
| Not completed | 0 | 1 | 0 | 1 | 0 | 1 | 2 | 1 | 0 | 1 | 3 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 |
| Withdrew: Investigator's discretion | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 1 |
TEAEs are any AEs with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.
| percentage of participants | Andecaliximab 0.3 mg/kg IV (SAD) | Andecaliximab 1.0 mg/kg IV (SAD) | Andecaliximab 2.5 mg/kg IV (SAD) | Andecaliximab 5.0 mg/kg IV (SAD) | Andecaliximab IV Combined (SAD) | Placebo Pooled (SAD) | Andecaliximab 0.3 mg/kg IV (MAD) | Andecaliximab 1.0 mg/kg IV (MAD) | Andecaliximab 2.5 mg/kg IV (MAD) | Andecaliximab 5.0 mg/kg IV (MAD) | Andecaliximab IV Combined (MAD) | Andecaliximab 150 mg SC (Adaptive MAD) | Andecaliximab IV+SC Combined (MAD) | Placebo Pooled (MAD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Experienced Any Treatment-Emergent Adverse Events (TEAEs) (SAD/MAD) | 0.0 | 20.0 | 20.0 | 60.0 | 25.0 | 25.0 | 25.0 | 75.0 | 62.5 | 62.5 | 56.3 | 50.0 | 54.8 | 62.5 |
Cmax is defined as the maximum concentration of drug.
| micrograms per milliliter (μg/mL) | Andecaliximab 0.3 mg/kg IV (SAD) | Andecaliximab 1.0 mg/kg IV (SAD) | Andecaliximab 2.5 mg/kg IV (SAD) | Andecaliximab 5.0 mg/kg IV (SAD) |
|---|---|---|---|---|
| Pharmacokinetic (PK) Parameter: Cmax (SAD) | 9.4 ± 3.28 | 32.7 ± 11.08 | 77.8 ± 20.67 | 210.0 ± 102.60 |
Cmax is defined as the maximum concentration of drug over the dosing interval. Data for Day 1 was based on the data collected from Day 1 through Day 8. Data for Day 29 was based on the data collected from Day 29 through Day 36.
| μg/mL | Andecaliximab 0.3 mg/kg IV (MAD) | Andecaliximab 1.0 mg/kg IV (MAD) | Andecaliximab 2.5 mg/kg IV (MAD) | Andecaliximab 5.0 mg/kg IV (MAD) | Andecaliximab 150 mg SC (Adaptive MAD) |
|---|---|---|---|---|---|
| Day 1 | 9.0 ± 3.23 | 33.7 ± 26.43 | 57.1 ± 13.66 | 95.3 ± 28.93 | NA ± NA |
| Day 29 | 10.3 ± 5.06 | 29.0 ± 10.89 | 66.6 ± 15.02 | 120.8 ± 21.15 | 33.5 ± 42.47 |
Ctau is defined as the observed drug concentration at the end of the dosing interval.
| μg/mL | Andecaliximab 0.3 mg/kg IV (MAD) | Andecaliximab 1.0 mg/kg IV (MAD) | Andecaliximab 2.5 mg/kg IV (MAD) | Andecaliximab 5.0 mg/kg IV (MAD) | Andecaliximab 150 mg SC (Adaptive MAD) |
|---|---|---|---|---|---|
| PK Parameter: Ctau (MAD) | NA ± NA | NA ± NA | 0.8 ± 2.36 | 27.2 ± 13.99 | 16.0 ± 15.99 |
AUCinf is defined as the area under the plasma concentration versus time curve extrapolated to infinite time.
| day*micrograms per milliliter(day*μg/mL) | Andecaliximab 0.3 mg/kg IV (SAD) | Andecaliximab 1.0 mg/kg IV (SAD) | Andecaliximab 2.5 mg/kg IV (SAD) | Andecaliximab 5.0 mg/kg IV (SAD) |
|---|---|---|---|---|
| PK Parameter: AUCinf (SAD) | 9.4 ± 4.44 | 66.6 ± 22.85 | 240.8 ± 23.69 | 817.3 ± 405.97 |
AUCtau is defined as the area under the plasma concentration versus time curve over the dosing interval. Data for Day 1 was based on the data collected from Day 1 through Day 8. Data for Day 29 was based on the data collected from Day 29 through Day 36.
| day*μg/mL | Andecaliximab 0.3 mg/kg IV (MAD) | Andecaliximab 1.0 mg/kg IV (MAD) | Andecaliximab 2.5 mg/kg IV (MAD) | Andecaliximab 5.0 mg/kg IV (MAD) | Andecaliximab 150 mg SC (Adaptive MAD) |
|---|---|---|---|---|---|
| PK Parameter: AUCtau (MAD) | NA ± NA | 79.2 ± 53.98 | 251.8 ± 88.15 | 784.8 ± 262.5 | 166.8 ± 164.53 |
AUClast is defined as the area under the plasma concentration versus time curve from time zero to the last observable concentration.
| day*μg/mL | Andecaliximab 0.3 mg/kg IV (SAD) | Andecaliximab 1.0 mg/kg IV (SAD) | Andecaliximab 2.5 mg/kg IV (SAD) | Andecaliximab 5.0 mg/kg IV (SAD) |
|---|---|---|---|---|
| PK Parameter: AUClast (SAD) | 7.7 ± 2.54 | 57.2 ± 26.96 | 212.4 ± 38.79 | 750.2 ± 412.42 |
Collected over SAD Cohorts: First dose date (Day 1) plus 30 days, MAD/Adaptive MAD Cohort: First dose date up to last dose date (Maximum: Day 29) plus 30 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Andecaliximab 0.3 mg/kg IV (SAD) | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Andecaliximab 1.0 mg/kg IV (SAD) | 0/5 (0%) | 1/5 (20%) | 0/5 (0%) |
| Andecaliximab 2.5 mg/kg IV (SAD) | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| Andecaliximab 5.0 mg/kg IV (SAD) | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Andecaliximab IV Combined (SAD) | 0/20 (0%) | 1/20 (5%) | 4/20 (20%) |
| Placebo Pooled (SAD) | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Andecaliximab 0.3 mg/kg IV (MAD) | 0/8 (0%) | 1/8 (12.5%) | 2/8 (25%) |
| Andecaliximab 1.0 mg/kg IV (MAD) | 0/8 (0%) | 1/8 (12.5%) | 6/8 (75%) |
| Andecaliximab 2.5 mg/kg IV (MAD) | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Andecaliximab 5.0 mg/kg IV (MAD) | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Andecaliximab IV Combined (MAD) | 0/32 (0%) | 2/32 (6.3%) | 18/32 (56.3%) |
| Andecaliximab 150 mg SC (Adaptive MAD) | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Andecaliximab IV+SC Combined (MAD) | 0/42 (0%) | 2/42 (4.8%) | 23/42 (54.8%) |
| Placebo Pooled (MAD) | 0/8 (0%) | 1/8 (12.5%) | 5/8 (62.5%) |
| Event | Andecaliximab 0.3 mg/kg IV (SAD) | Andecaliximab 1.0 mg/kg IV (SAD) | Andecaliximab 2.5 mg/kg IV (SAD) | Andecaliximab 5.0 mg/kg IV (SAD) | Andecaliximab IV Combined (SAD) | Placebo Pooled (SAD) | Andecaliximab 0.3 mg/kg IV (MAD) | Andecaliximab 1.0 mg/kg IV (MAD) | Andecaliximab 2.5 mg/kg IV (MAD) | Andecaliximab 5.0 mg/kg IV (MAD) | Andecaliximab IV Combined (MAD) | Andecaliximab 150 mg SC (Adaptive MAD) | Andecaliximab IV+SC Combined (MAD) | Placebo Pooled (MAD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 0/5 | 1/5 | 0/5 | 0/5 | 1/20 | 0/4 | 0/8 | 1/8 | 0/8 | 0/8 | 1/32 | 0/10 | 1/42 | 0/8 |
| Cytomegalovirus infectionInfections and infestations | 0/5 | 1/5 | 0/5 | 0/5 | 1/20 | 0/4 | 0/8 | 0/8 | 0/8 | 0/8 | 0/32 | 0/10 | 0/42 | 0/8 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/5 | 1/5 | 0/5 | 0/5 | 1/20 | 0/4 | 0/8 | 0/8 | 0/8 | 0/8 | 0/32 | 0/10 | 0/42 | 0/8 |
| AnaemiaBlood and lymphatic system disorders | 0/5 | 0/5 | 0/5 | 0/5 | 0/20 | 0/4 | 0/8 | 0/8 | 0/8 | 0/8 | 0/32 | 0/10 | 0/42 | 1/8 |
| HypersensitivityImmune system disorders | 0/5 | 0/5 | 0/5 | 0/5 | 0/20 | 0/4 | 1/8 | 0/8 | 0/8 | 0/8 | 1/32 | 0/10 | 1/42 | 0/8 |
| Event | Andecaliximab 0.3 mg/kg IV (SAD) | Andecaliximab 1.0 mg/kg IV (SAD) | Andecaliximab 2.5 mg/kg IV (SAD) | Andecaliximab 5.0 mg/kg IV (SAD) | Andecaliximab IV Combined (SAD) | Placebo Pooled (SAD) | Andecaliximab 0.3 mg/kg IV (MAD) | Andecaliximab 1.0 mg/kg IV (MAD) | Andecaliximab 2.5 mg/kg IV (MAD) | Andecaliximab 5.0 mg/kg IV (MAD) | Andecaliximab IV Combined (MAD) | Andecaliximab 150 mg SC (Adaptive MAD) | Andecaliximab IV+SC Combined (MAD) | Placebo Pooled (MAD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/5 | 0/5 | 0/5 | 1/5 | 1/20 | 0/4 | 0/8 | 3/8 | 2/8 | 0/8 | 5/32 | 0/10 | 5/42 | 3/8 |
| Colitis ulcerativeGastrointestinal disorders | 0/5 | 0/5 | 0/5 | 0/5 | 0/20 | 0/4 | 0/8 | 0/8 | 0/8 | 0/8 | 0/32 | 0/10 | 0/42 | 2/8 |
| FatigueGeneral disorders | 0/5 | 0/5 | 0/5 | 0/5 | 0/20 | 0/4 | 0/8 | 2/8 | 1/8 | 0/8 | 3/32 | 0/10 | 3/42 | 1/8 |
| PyrexiaGeneral disorders | 0/5 | 0/5 | 0/5 | 0/5 | 0/20 | 0/4 | 0/8 | 0/8 | 0/8 | 0/8 | 0/32 | 0/10 | 0/42 | 2/8 |
| NasopharyngitisInfections and infestations | 0/5 | 0/5 | 0/5 | 0/5 | 0/20 | 1/4 | 1/8 | 0/8 | 0/8 | 2/8 | 3/32 | 0/10 | 3/42 | 0/8 |
| DizzinessNervous system disorders | 0/5 | 0/5 | 0/5 | 0/5 | 0/20 | 0/4 | 0/8 | 0/8 | 1/8 | 0/8 | 1/32 | 0/10 | 1/42 | 2/8 |
| HeadacheNervous system disorders | 0/5 | 0/5 | 0/5 | 0/5 | 0/20 | 0/4 | 0/8 | 0/8 | 0/8 | 2/8 | 2/32 | 1/10 | 3/42 | 2/8 |
| Parotid gland enlargementGastrointestinal disorders | 0/5 | 0/5 | 0/5 | 1/5 | 1/20 | 0/4 | 0/8 | 0/8 | 0/8 | 0/8 | 0/32 | 0/10 | 0/42 | 0/8 |
| Salivary gland painGastrointestinal disorders | 0/5 | 0/5 | 0/5 | 1/5 | 1/20 | 0/4 | 0/8 | 0/8 | 0/8 | 0/8 | 0/32 | 0/10 | 0/42 | 0/8 |
| ToothacheGastrointestinal disorders | 0/5 | 0/5 | 0/5 | 1/5 | 1/20 | 0/4 | 0/8 | 0/8 | 0/8 | 0/8 | 0/32 | 0/10 | 0/42 | 0/8 |
The Safety Analysis Set included participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Andecaliximab 0.3 mg/kg IV (SAD) | Andecaliximab 1.0 mg/kg IV (SAD) | Andecaliximab 2.5 mg/kg IV (SAD) | Andecaliximab 5.0 mg/kg IV (SAD) | Placebo Pooled (SAD) | Andecaliximab 0.3 mg/kg IV (MAD) | Andecaliximab 1.0 mg/kg IV (MAD) | Andecaliximab 2.5 mg/kg IV (MAD) | Andecaliximab 5.0 mg/kg IV (MAD) | Andecaliximab 150 mg SC (Adaptive MAD) | Placebo Pooled (MAD) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 42 ± 11.3 | 37 ± 11.3 | 45 ± 15.4 | 42 ± 12.9 | 41 ± 15.1 | 42 ± 13.9 | 39 ± 11.7 | 38 ± 13.7 | 50 ± 9.8 | 48 ± 8.8 | 44 ± 15.8 | 43 ± 12.4 |
| Sex: Female, Male(Participants) | Andecaliximab 0.3 mg/kg IV (SAD) | Andecaliximab 1.0 mg/kg IV (SAD) | Andecaliximab 2.5 mg/kg IV (SAD) | Andecaliximab 5.0 mg/kg IV (SAD) | Placebo Pooled (SAD) | Andecaliximab 0.3 mg/kg IV (MAD) | Andecaliximab 1.0 mg/kg IV (MAD) | Andecaliximab 2.5 mg/kg IV (MAD) | Andecaliximab 5.0 mg/kg IV (MAD) | Andecaliximab 150 mg SC (Adaptive MAD) | Placebo Pooled (MAD) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 3 | 1 | 3 | 3 | 5 | 3 | 5 | 2 | 6 | 3 | 38 |
| Male | 1 | 2 | 4 | 2 | 1 | 3 | 5 | 3 | 6 | 4 | 5 | 36 |
| Ethnicity (NIH/OMB)(Participants) | Andecaliximab 0.3 mg/kg IV (SAD) | Andecaliximab 1.0 mg/kg IV (SAD) | Andecaliximab 2.5 mg/kg IV (SAD) | Andecaliximab 5.0 mg/kg IV (SAD) | Placebo Pooled (SAD) | Andecaliximab 0.3 mg/kg IV (MAD) | Andecaliximab 1.0 mg/kg IV (MAD) | Andecaliximab 2.5 mg/kg IV (MAD) | Andecaliximab 5.0 mg/kg IV (MAD) | Andecaliximab 150 mg SC (Adaptive MAD) | Placebo Pooled (MAD) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 5 | 5 | 5 | 5 | 4 | 8 | 8 | 8 | 8 | 10 | 8 | 74 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Andecaliximab 0.3 mg/kg IV (SAD) | Andecaliximab 1.0 mg/kg IV (SAD) | Andecaliximab 2.5 mg/kg IV (SAD) | Andecaliximab 5.0 mg/kg IV (SAD) | Placebo Pooled (SAD) | Andecaliximab 0.3 mg/kg IV (MAD) | Andecaliximab 1.0 mg/kg IV (MAD) | Andecaliximab 2.5 mg/kg IV (MAD) | Andecaliximab 5.0 mg/kg IV (MAD) | Andecaliximab 150 mg SC (Adaptive MAD) | Placebo Pooled (MAD) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Race — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race — Asian | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Race — Black | 2 | 2 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 0 | 8 |
| Race — Native Hawaiian or Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race — White | 2 | 3 | 5 | 5 | 3 | 7 | 7 | 8 | 8 | 8 | 8 | 64 |
| Race — Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race — Not Permitted | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Ran from Mar 2013 to primary completion in Jan 2015, 21 months.
Results were first posted in Feb 2021, 6 years after primary completion.
Of 58 industry-sponsored phase 1 interventional studies under Colitis, Ulcerative, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's 21 months is above that.
Counting every sponsor, half of 84 studies reached it within 13 months; a quarter within 8 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Andecaliximab